Percutaneous coronary intervention and atrial fibrillation: the triple therapy dilemma

Area of Science:

• Cardiology
• Internal Medicine
• Pharmacology

Background:

• Atrial fibrillation (AF) is the most common cardiac arrhythmia.
• Chronic oral anticoagulation (OAC) is standard for preventing stroke in high-risk patients.
• Co-existing coronary artery disease (CAD) affects 20-30% of AF patients, increasing management complexity, especially in the elderly.

Purpose of the Study:

• To review current evidence for managing patients with both AF and CAD.
• To identify unmet needs in this patient population.
• To discuss future perspectives for treatment strategies.

Main Methods:

• This viewpoint synthesizes existing clinical evidence and guidelines.
• It focuses on the challenges of triple antithrombotic therapy (TAT).
• The discussion addresses treatment dilemmas and future research directions.

Main Results:

• Triple antithrombotic therapy (TAT), combining OAC with dual antiplatelet therapy (DAPT), is often necessary for AF patients with CAD undergoing procedures like percutaneous coronary intervention (PCI).
• However, TAT significantly increases the risk of bleeding complications.
• Balancing antithrombotic efficacy and bleeding risk is a critical challenge.

Conclusions:

• The management of AF patients with CAD, particularly those requiring TAT, presents a significant clinical challenge due to the increased bleeding risk.
• Further research is needed to optimize antithrombotic strategies and minimize complications in this high-risk group.
• Personalized treatment approaches are essential for effective and safe management.